Revolutionizing Clinical Research: A Transformative Initiative Led by Linden Capital Partners and Ontario Teachers’ Pension Plan

Clinical research plays a crucial role in developing life-saving therapies and advancing medical knowledge. However, the industry faces numerous challenges, including inefficiencies and a lack of connectivity among stakeholders. Recognizing the need for change, Linden Capital Partners and Ontario Teachers' Pension Plan have joined forces to launch an innovative initiative focused on clinical research advancement. Led by industry experts Dr. John Potthoff and Ms. Margaret Keegan, this transformative platform aims to revolutionize the clinical research ecosystem through strategic investments and cutting-edge technology.

The vision of this initiative is to create a more unified and efficient clinical research ecosystem. By leveraging mergers and acquisitions (M&A) and advanced technologies, the platform seeks to enhance collaboration across all aspects of clinical research. From patient engagement to regulatory submissions, every phase of the research process will be seamlessly connected and optimized.

Dr. John Potthoff, the Chairperson of Elligo Health Research®, will lead this groundbreaking initiative. With over 30 years of leadership experience in the life sciences and pharmaceutical services sectors, Dr. Potthoff brings a wealth of knowledge to the table. His expertise in scaling and growing businesses will be instrumental in driving meaningful change in the clinical research industry.

"We believe our collaboration is a potential game-changer for clinical research. We see a significant gap in the industry and believe this strategic alliance will drive meaningful change and opportunity," said Dr. Potthoff. "By integrating leading companies and leveraging advanced technologies, we aim to create a cohesive and interconnected clinical research environment. Recognizing the unique needs of each therapeutic and scientific area, we aim to streamline processes, enhance efficiencies, and foster collaborations that benefit all stakeholders, especially patients."

Assisting Dr. Potthoff in this endeavor is Ms. Margaret Keegan, an industry luminary with extensive experience in clinical development. Having held executive roles at major pharmaceutical and Contract Research Organization (CRO) companies, she brings a wealth of expertise to the initiative. As the former Chair of the Board for CDISC, the clinical research data standards organization, and the current CEO of RQM+, Ms. Keegan is committed to catalyzing positive change in the clinical research industry.

"I am excited to collaborate with Dr. Potthoff, Linden, and Ontario Teachers' to realize our shared vision," expressed Ms. Keegan. "We recognize the inefficiencies and shortcomings of clinical research services that impact patients, research sites, sponsors, and regulators, leading to delays in getting critical therapies to patients in need. Our commitment is to address these challenges head-on and catalyze positive change in our industry."

Linden Capital Partners is a Chicago-based private equity firm exclusively focused on the healthcare industry. With a specialized healthcare strategy and integrated private equity and operating expertise, Linden has invested in over 40 healthcare companies, encompassing over 325 total transactions. Their dedication to the healthcare sector positions them as a suitable partner for this transformative initiative.

Ontario Teachers' Pension Plan Board is a global investor with net assets of $249.8 billion. As a fully funded defined benefit pension plan, Ontario Teachers' brings deep expertise in various sectors and industries. Their commitment to shaping a better future aligns with the initiative's goal of advancing clinical research to improve patient outcomes.

In conclusion, the collaboration between Linden Capital Partners and Ontario Teachers' Pension Plan marks a significant milestone in the field of clinical research. This transformative initiative led by Dr. John Potthoff and Ms. Margaret Keegan aims to revolutionize the clinical research ecosystem. By investing in exceptional companies and deploying cutting-edge technology, the platform seeks to foster seamless connections and collaborations among patients, research sites, pharmaceutical companies, and the broader clinical research community. With a vision for a more unified and efficient clinical research ecosystem, this initiative is poised to make a lasting impact on the industry and benefit patients worldwide.